NVO Stock - Novo Nordisk A/S
Unlock GoAI Insights for NVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $290.40B | $232.26B | $176.95B | $140.80B | $126.95B |
| Gross Profit | $245.88B | $196.50B | $148.51B | $117.14B | $106.01B |
| Gross Margin | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% |
| Operating Income | $128.34B | $102.57B | $74.81B | $58.64B | $54.13B |
| Net Income | $100.99B | $83.68B | $55.52B | $47.76B | $42.14B |
| Net Margin | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% |
| EPS | $22.67 | $18.67 | $12.26 | $10.40 | $9.03 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit WebsiteEarnings History & Surprises
NVOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.90 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.77 | $1.02 | +32.5% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.93 | $0.97 | +4.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.92 | $0.92 | 0.0% | = MET |
Q1 2025 | Feb 5, 2025 | $0.88 | $0.91 | +3.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.87 | $0.88 | +1.4% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.70 | $0.66 | -5.9% | ✗ MISS |
Q2 2024 | May 2, 2024 | $0.74 | $0.82 | +10.5% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.65 | $0.71 | +9.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.71 | $0.71 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $0.67 | $0.63 | -6.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $0.63 | $0.63 | 0.0% | = MET |
Q1 2023 | Feb 1, 2023 | $0.41 | $0.41 | 0.0% | = MET |
Q4 2022 | Nov 2, 2022 | $0.42 | $0.43 | +2.4% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.44 | $0.42 | -4.5% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $0.43 | $0.47 | +9.3% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $0.35 | $0.37 | +5.7% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.40 | $0.42 | +5.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.38 | $0.43 | +13.2% | ✓ BEAT |
Latest News
Frequently Asked Questions about NVO
What is NVO's current stock price?
What is the analyst price target for NVO?
What sector is Novo Nordisk A/S in?
What is NVO's market cap?
Does NVO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NVO for comparison